More than half of patients who stop weight-loss drugs restart within a year Researchers found that people taking newer medications, such as tirzepatide, were 41% less likely to discontinue than those taking older drugs, such as liraglutide.…
Health news round-up: elecoglipron, antibiotic resistant E. coli and low blood pressure risk in frailty The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
Drugs used for airway clearance in critically ill patients found to cause harm Researchers found that carbocisteine increased the risk of gastrointestinal bleeding, while hypertonic saline was associated with an increased risk of nebulisation-related harms in critically ill patients on mechanical ventilators.…
MS drug found to benefit patients with more advanced disease Researchers reported that ocrelizumab significantly reduced the risk of disability worsening in wheelchair-dependent patients.…
Virtual clinics could help improve access to adverse drug reaction services for children Three-quarters of adverse drug reactions assessed by a virtual clinic during the COVID-19 pandemic were related to antibiotics, study authors reported.…
Tezepelumab may reduce need for oral corticosteroids in severe asthma Study authors said their results “show the potential of tezepelumab to reduce maintenance oral corticosteroid use while maintaining asthma control and without compromising the efficacy outcomes”.…
Health news round-up: anaphylaxis, pain management in women’s health and Tourette’s treatment The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
Electronic medical records can identify prescribing patterns for antibiotic allergies, study results show Following analysis of 342 children's electronic medical records, researchers identified 67 children with a possible or probable antibiotic allergy.…
Phase III retatrutide study demonstrates 30% weight loss Researchers found that at 104 weeks of the TRIUMPH-1 trial, participants with severe obesity who took retatrutide 9mg or 12mg achieved up to 30% weight loss.…
MHRA asks for views on rare disease therapy plans The ‘Rare disease therapies regulatory framework’ would incorporate a compressed regulatory pathway, aimed to reduce the cost of developing rare disease therapies and make them more affordable, the MHRA said.…
